SNDX - Syndax Announces Presentation at 42nd Annual J.P. Morgan Healthcare Conference

PR Newswire

WALTHAM, Mass. , Jan. 2, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Michael A. Metzger , Chief Executive Officer of Syndax, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024 at 5:15 p.m. PT / 8:15 p.m. ET .

A live webcast of the fireside chat can be accessed from the Investor section of the Company's website at www.syndax.com , where a replay of the event will also be available for a limited time.

About Syndax

Syndax Pharmaceuticals is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include revumenib, a highly selective inhibitor of the menin–KMT2A binding interaction, and axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. For more information, please visit www.syndax.com or follow the Company on Twitter and LinkedIn .

Syndax Contact

Sharon Klahre
Syndax Pharmaceuticals, Inc.
sklahre@syndax.com
Tel 781.684.9827

SNDX-G

SOURCE Syndax Pharmaceuticals, Inc.